glp-1 diarrhea legal team in west virginia side effect lawsuit GLP-1RA Essentials in Gastroenterology: Side Effect Management Direct Meds GLP-1: How Much

Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association [published online ahead of print March 8, 2025]

Plans that apply these broader criteria recognize that metabolic dysfunction and excess weight are interconnected risk factors warranting early intervention

Compounded semaglutide starts at $149/mo, with access to clinical guidance

Previous shortages of GLP-1 RAs impacted patient care, leading to concerns that these medications should be reserved for patients with diabetes rather than weight loss in otherwise healthy individuals

HDL-C, high-density lipoprotein cholesterol

CMS is proposing temporary expansions of Medicare and Medicaid coverage of GLP-1s for obesity through demonstration programs CMS initially proposed a two-step approach to expanding coverage of GLP-1s for obesity in Medicare a temporary payment demonstration for 2026, known as the Medicare GLP-1 Bridge, and a new Center for Medicare and Medicaid Innovation (CMMI) model, known as the BALANCE Model, that was originally scheduled to begin in January 2027 and end in December 2031